Akribion Therapeutics at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Akribion Therapeutics brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on a programmable Cas12a2 nuclease that destroys cells carrying a chosen genetic signature. It covers killing HPV-positive head and neck tumour cells and targeting a wider range of disease-relevant genomic alterations.
| Organization | ESGCT 2026 Attendance |
|---|---|
Develops RNA-guided Cas12a2 nuclease technology to selectively destroy unwanted cells, starting with HPV-positive head and neck cancer. | Talk Wed Oct 28 11:00am–10:30am Next‑Generation Cancer Targeting: Harnessing CRISPR‑Cas12a2 to Eliminate HPV‑Positive Tumor Cells. Cancer gene and cell therapyGene and epigenome editing Poster Wed Oct 28 1:30pm–3:30pm Targeting diverse disease-relevant genomic alterations using a novel programmable Cas12a2 CRISPR nuclease |
Instantly find 20 buyers from Akribion Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction